The effect of the REG2 Anticoagulation System on thrombin generation kinetics: A pharmacodynamic and pharmacokinetic first-in-human study

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 3, 2014, Pages 275-284

  Vavalle, J P ^b   Rusconi, C P ^c   Zelenkofske, S ^d   Wargin, W A ^e   Ortel, T L ^f   Alexander, J H ^b   Povsic, T J ^b   Becker, R C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Regado Biosciences   (United States)

^d Regado Biosciences Inc   (United States)

^e PK PM Associates LLC   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Antidote; Calibrated Automated Thrombogram ; Factor IXa inhibition; Reversibility; Thrombin generation kinetics

Indexed keywords

ANIVAMERSEN; PEGNIVACOGIN; PLACEBO; THROMBIN; TRYPSIN INHIBITOR; ANTICOAGULANT AGENT; APTAMER; BLOOD CLOTTING FACTOR 9A;

ADULT; ANTICOAGULATION; ARTICLE; AUTOANALYZER; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; ENDOGENOUS THROMBIN POTENTIAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LAG; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PEAK THROMBIN GENERATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; REG2 ANTICOAGULATION SYSTEM; REPEATED DRUG DOSE; SINGLE DRUG DOSE; THROMBIN TIME; VELOCITY INDEX; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DEVICES; METABOLISM; PROCEDURES; PROSPECTIVE STUDY;

ADULT; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR IXA; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; THROMBIN; THROMBIN TIME;

EID: 84906938445     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1081-6     Document Type: Article

References (18)

1. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM (2004) Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2:402-413 (Pubitemid 40185650)
2. Vavalle JP, Rusconi CP, Zelenkofske S, Wargin WA, Alexander JH, Becker RC (2012) A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. J Thromb Haemost 10(7):1303-1311
3. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S (2002) The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32:249-253 (Pubitemid 37490547)
4. Luddington R, Baglin T (2004) Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2:1954-1959 (Pubitemid 40192749)
5. Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, Alexander JH, Rusconi CP, Becker RC (2011) Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 32:21-31
6. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C (2005) Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 93:475-480 (Pubitemid 40392535)
7. Brummel KE, Butenas S, Mann KG (1999) An integrated study of fibrinogen during blood coagulation. J Biol Chem 274:22862-22870
8. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW (2007) Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol 139:106-112 (Pubitemid 47389917)
9. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP (2007) Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 138:769-774 (Pubitemid 47313221)
10. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6:1327-1333 (Pubitemid 352016312)
11. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA (2006) Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296:397-402 (Pubitemid 44127523)
12. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, Dogne JM (2009) Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 59:160-166
13. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG (1998) Blood coagulation in hemophilia A and hemophilia C. Blood 91:4581-4592 (Pubitemid 28270306)
14. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114:2490-2497 (Pubitemid 44901522)
15. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP (2008) Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117:2865-2874 (Pubitemid 351787073)
16. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor ixa inhibitor. J Thromb Haemost 6:789-796 (Pubitemid 351524539)
17. Brummel KE, Paradis SG, Butenas S, Mann KG (2002) Thrombin functions during tissue factor-induced blood coagulation. Blood 100:148-152 (Pubitemid 35177440)
18. Lawrie AS, Kitchen S, Purdy G, Mackie IJ, Preston FE, Machin SJ (1998) Assessment of actin FS and actin FSL sensitivity to specific clotting factor deficiencies. Clin Lab Haematol 20:179-186 (Pubitemid 28313580)